Best response rate at 3 months. (A) Best response at 3 months on 26 of the 29 patients included in the efficacy-evaluable set according to disease histology (DLBCL NOS; tDLBCL; and HGBL with MYC and BCL2 and/or BCL6 rearrangements) and in the whole cohort. (B) Subgroup analysis of the ORR for key baseline and clinical covariates. ∗Indicates double expressor excluding double- or triple-hit lymphoma (total of 23 patients). † indicates cell of origin by the Hans algorithm. ‡ indicates the sum of the product of the perpendicular diameters of up to 6 target measurable nodes and extranodal sites. § indicates the maximum standardized uptake value in target lesion. The 95% CI was calculated with the use of the Wilson/Brown method. ECOG PS, Eastern Cooperative Oncology Group performance score; HGBL, high-grade B-cell lymphoma; IPI, International Prognostic Index; LDH, lactate dehydrogenase; NOS, not otherwise specified; SPD, sum of the product of the perpendicular diameters of up to 6 target measurable nodes and extranodal sites; tDLBCL, DLBCL transformed from indolent histology.